• Publications
  • Influence
Updated research nosology for HIV-associated neurocognitive disorders
In 1991, the AIDS Task Force of the American Academy of Neurology published nomenclature and research case definitions to guide the diagnosis of neurologic manifestations of HIV-1 infection. Now, 16Expand
  • 1,928
  • 243
  • PDF
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy
Objectives: This is a cross-sectional, observational study to determine the frequency and associated features of HIV-associated neurocognitive disorders (HAND) in a large, diverse sample of infectedExpand
  • 1,583
  • 107
  • PDF
HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors
Combination antiretroviral therapy (CART) has greatly reduced medical morbidity and mortality with HIV infection, but high rates of HIV-associated neurocognitive disorders (HAND) continue to beExpand
  • 1,104
  • 86
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.
OBJECTIVE To evaluate whether penetration of a combination regimen into the central nervous system (CNS), as estimated by the CNS Penetration-Effectiveness (CPE) rank, is associated with lowerExpand
  • 724
  • 54
  • PDF
Immunocytochemical quantitation of human immunodeficiency virus in the brain: Correlations with dementia
The pathogenesis of human immunodeficiency virus (HIV)‐associated dementia is unclear, and the underlying pathological substrate has been a matter of debate. In a prospectively clinicallyExpand
  • 657
  • 52
The International HIV Dementia Scale: a new rapid screening test for HIV dementia
Objective:HIV dementia is an important neurological complication of advanced HIV infection. The use of a cross-cultural screening test to detect HIV dementia within the international community isExpand
  • 389
  • 52
Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia.
Activated monocytes release a number of substances, including inflammatory cytokines and eicosanoids, that are highly toxic to cells of the central nervous system. Because monocytic infiltration ofExpand
  • 576
  • 49
  • PDF
HIV Dementia Scale: a rapid screening test.
HIV dementia has an annual incidence of 7% after AIDS development and eventually affects 20% of all HIV-infected persons. Accurate and early diagnosis of HIV dementia can lead to optimizedExpand
  • 360
  • 41
HIV-associated neurologic disease incidence changes:
This study examined the temporal trends in the incidence rates of HIV dementia, cryptococcal meningitis, toxoplasmosis, progressive multifocal leukoencephalopathy, and CNS lymphoma from January 1990Expand
  • 549
  • 31
HIV-associated neurocognitive disorder — pathogenesis and prospects for treatment
In the past two decades, several advancements have improved the care of HIV-infected individuals. Most importantly, the development and deployment of combination antiretroviral therapy (CART) hasExpand
  • 313
  • 31